Background: Utilization of energy-dense lipid fuels is critical to the rapid development and growth of neonates.
Introduction
The early postnatal period poses the greatest challenge to the energy balance of neonates, which must rapidly adapt from the utilization of carbohydrates supplied by the mother in utero to lipids supplied via milk. To cope with this challenge, the ability of neonates to oxidize FAs from endogenous lipid sources or from milk fat develops rapidly in various tissues and remains high throughout the suckling period (1, 2) . Ketogenesis emerges in the liver after the increased FA oxidation and provides a fuel source for extrahepatic tissues. This adaptive evolution occupies an important position in mammalian survival and is critical to the rapid development and growth of neonates after birth. However, the capacity of newborn pigs to oxidize FAs is only ;32% of 24-d-old pigs (3) . Furthermore, >90% of oleate taken up by piglet hepatocytes is re-esterified with limited flux through b-oxidation (4), and suckling pigs remain hypoketonemic despite elevated dietary fat (5, 6) . Studies in liver tissue demonstrated that at least 75% of the acetyl-CoA generated from hepatic FA b-oxidation is converted to acetate rather than ketone bodies (7) . These observations imply unique aspects of FA metabolism and its regulation in neonatal pigs.
The pivotal role of PPARa in the regulation of FA oxidation was highlighted greatly in the past 2 decades. This transcription factor controls expression of genes encoding carnitine palmitoyltransferase (CPT) 8 I, mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (mHMGCS), and acyl-CoA oxidase (ACO), thereby inducing FA catabolism. PPARa can be activated by either its endogenous ligands, such as long-chain FAs (LCFAs) and eicosanoids, or pharmacologic agonists, including fibrates (8) . Clofibrate, as a PPARa agonist, was used extensively in studies examining FA metabolism and regulation. Administration of clofibrate increases cellular FA uptake, transport, and oxidation in rodent species specifically for the very-long-chain FAs (VLCFAs) that are oxidized initially in peroxisomes. For instance, the oxidation of erucic acid (22:1n-9 ) is increased 5-fold in hepatocytes isolated from rats fed clofibrate (9) . The effects of clofibrate on gene expression and enzyme activities were well documented in the review by Bremer (10) .
To understand the inadequacy of FA oxidation in neonatal pigs after birth, we investigated the regulatory role of PPARa on the key enzymes that regulate FA b-oxidation by providing exogenous clofibrate stimulation. We found that the activities of CPT, ACO, and catalase in liver were significantly increased in neonatal pigs fed clofibrate via milk replacer for 14 d (11) . We further tested the in vitro effects of clofibrate on hepatic FA oxidation using radiolabeled palmitic acid (16:0). Clofibrate increased rates of hepatic peroxisomal and mitochondrial b-oxidation by 60% and 186%, respectively (12) . The increase of FA b-oxidation is consistent with the increase in the key enzyme activities, demonstrating that clofibrate effectively induces the expression of key enzymes related to FA oxidation and that induction is mediated by PPARa in neonatal pigs. Actually, PPARa is likely to play a central role not only in the nutritional transition period in newborn pigs but also in the adaptation to food deprivation in weaning pigs (13) .
Although data from metabolic studies in vitro verified the role of clofibrate in increasing FA oxidation by activation of PPARa, to our knowledge, the effectiveness of administrating clofibrate on dietary TG utilization in vivo was never tested in neonatal animals. Moreover, clofibrate has been used in humans for lowing blood TGs and cholesterol since the 1960s, but data illustrating the effects of clofibrate on in vivo FA oxidation are very limited. PPARa is highly expressed in cells that have high FA catabolic rates, including not only the liver but also the kidney, heart, and skeletal muscle (14) . Therefore, we hypothesized that the increased hepatic FA oxidation observed in vitro in neonatal pigs administered clofibrate would improve the efficiency of milk fat utilization in vivo. To test our hypothesis, we studied the capacity of FA oxidation in neonatal pigs using respiration chambers after gastric infusion of control and clofibrate-treated pigs with isoenergetic amounts of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]TG. Because peroxisomal b-oxidation develops rapidly after birth (15, 16) and because 60% of the energy in sow milk is derived from TGs containing LCFAs and VLCFAs, the effects of clofibrate on LCFA and VLCFA oxidation in both mitochondria and peroxisomes were investigated using [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]oleic acid (18:1n-9) and erucic acid TG.
Materials and Methods
Pigs. Thirty newborn male pigs (1.61 6 0.21 kg) from 5 litters (6 pigs per litter) were used. The pigs were assigned to 2 groups (control vs. clofibrate) based on body weight (BW) and then kept with their mothers. The clofibrate-treated pigs were orogastrically gavaged with clofibrate (75 mg/kg BW) in 2 mL of 2% Tween 80, and the control pigs were gavaged with 2 mL of Tween 80 vehicle only at 0800 for each of 4 consecutive days. On day 4, all pigs were removed from the sow after the last gavage, and BW was recorded at the transfer. In vivo and in vitro FA oxidation was then assessed as described by Odle et al. (17) . All procedures were approved by the Institutional Animal Care and Use Committee of North Carolina State University.
TG synthesis. Oleic acid TG and erucic acid TG were synthesized from glycerol and free oleic and erucic acids using p-toluenesulfonic acid as a catalyst. The syntheses were conducted in a glass reflux unit. The reactants were refluxed at 135°C under N 2 for 60-72 h as described by Weeler et al. (18) . The synthesized TGs were purified by alkaline/ ethanolic extraction, and purity ($95%) was confirmed chromatographically using an HPLC system (Waters) equipped with a photodiode array detector (19) . The synthesis of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]oleic acid and erucic acid TGs followed the same procedure as described above using [ (21) . The schedule and duration of the expired CO 2 collection was patterned following the study by Heo et al. (20) , and the pigs were killed by American Veterinary Medical Association-approved electrocution when the experiment ended, after 24 h of collection. The rate and extent of FA oxidation were computed from the kinetics of 14 CO 2 expiration measured continuously over 24 h (22) . TG utilization rates were expressed in terms of ATP yield [mmol ATP/(kg 0.75 Á min)], which corrected for differences in molar energy content between oleic acid TG and erucic acid TG (20) . 
and 10 mmol/L ATP (pH 7.4). Incubations were terminated at 30 min by injecting 0.5 mL of 30% HClO 4 , and the accumulation of radioactivity in CO 2 and acid-soluble products (ASPs) was determined using liquid scintillation spectrometry (Beckman Coulter).
Enzyme activity and mRNA expression. Activity of CPT I was determined in isolated mitochondria (23) . Liver mitochondria were prepared from the fresh liver samples (24) , and intactness of mitochondria was evaluated using the respiratory control ratio method (25) . ACO activity was determined fluorometrically in liver homogenates (26) . Homogenates were prepared in an ice-cold buffer containing 250 mmol/L sucrose, 1 mmol/L EDTA, and 1% ethanol. The assay was conducted with homogenates (0.6 6 0.035 mg of protein) cultured in a dark room at 37°C in 0.5 mL (final volume) of a medium with or without 35 mmol/L palmitoyl-CoA for 20 min. The medium contained 60 mmol/L Tris-HCl, 50 mmol/L FAD, 170 mmol/L CoA, 1 mmol/L scopoletin, and 6% BSA. After termination with 2 mL of borate buffer (0.1 mol/L, pH 10), 200 mL of the incubated medium was transferred into a 96-well plate and measured in a BioTek reader (Synergy HT) with emission at 460 nm and excitation at 360 nm (BioTek Instruments). The standard curve was established using H 2 O 2 (30%, wt:wt) and 150 IU of peroxidase under the same incubation conditions and measurement.
The abundances of mRNA in peroxisome proliferator-activated receptor a (PPARa), CPT I, CPT II, ACO, and mHMGCS in the liver were analyzed using real-time PCR. Total RNA was isolated from the liver samples using Qiagen RNeasy Mini Kit. The integrity of isolated RNA was confirmed using gel electrophoresis with SYBR Safe DNA gel stain (Invitrogen Life Technologies). The extracted RNA was treated with TuboDNase (Ambion) and then transcribed using an iScript Select cDNA Synthesis Kit (Bio-Rad Laboratories). Real-time PCR was performed using the MyiQ Single Color Real-Time PCR Detection System (Bio-Rad Laboratories). All samples were analyzed in triplicate. Each reaction contained cDNA (200-500 ng) and reverse and forward primers (200-600 nM). All templates were amplified for 40 cycles under the following conditions: denaturation for 30 s at 95°C, primer annealing and extension for 30 s at 60°C. Data were collected at the end of each elongation phase. The primer pairs used are shown in Supplemental Table 1 . qPCR efficiencies were acquired by the amplification of a dilution series of cDNA, and efficiencies of all target genes and the housekeeping gene (GAPDH) used in this study approximated 100%. At the end of the amplification, melt curve analysis was used to validate the absence of nonspecific products and primer dimmers. Data were calculated and analyzed for the relative changes in gene expression using the 2 2DDCT method (27) . Relative mRNA abundance of each target gene was normalized to the control group.
Chemicals. The [1- 14 C]oleic acid and erucic acid FAs were purchased from American Radiolabeled Chemicals. The clofibrate was purchased from Cayman Chemicals. NaOH, HClO 4 , and HCl were purchased from Thermo Fisher Scientific, and all other chemicals were obtained from Sigma-Aldrich.
Statistical analysis. The BW and daily gain of control and clofibratetreated pigs were analyzed using the t test procedure of SAS. Data from the measurements of TG utilization in vivo were calculated as described by Heo et al. (20) . Enzyme-specific activities and mRNA expressions were subjected to analysis of variance according to a randomized complete block design with 2 treatments, with and without clofibrate, blocked by replicate. A simple linear regression was performed for the CO 2 expiration rate with time, and the parameters were estimated using the proc REG procedure of SAS. The sigmoidal substrate saturation kinetics analysis for accumulative TG utilization was conducted using the logistic model. The maximal utilization and the time of reaching half-maximal utilization were estimated with the equations obtained by the NLIN procedure of SAS (20) . Data for utilization rate, maximal utilization, and in vitro FA oxidation were analyzed with a split-plot design, including a main plot (control vs. clofibrate) of randomized blocks and a subplot modeling TG (tri-oleic acid vs. tri-erucic acid) effects, time effects, and interactions. Multiple comparisons among the 4 treatments were performed using a TukeyÕs test, with significance declared when P # 0.05 and tendencies noted when 0.05 # P # 0.1.
Results
Growth performance. The BW of the pigs increased 25% by the end of the experiment (4 d, 2.00 6 0.08 kg) compared with the initial BW (1.61 6 0.06 kg, P < 0.05), but clofibrate had no effect on either the BWor the daily gain (P > 0.12). The mean 6 SEM BWand daily gain were 2.01 6 0.08 and 0.14 6 0.02 kg for the control pigs and 2.0 6 0.08 and 0.12 6 0.02 kg for the clofibrate-treated pigs.
TG utilization. The expiration rate of CO 2 (Fig. 1A) decreased linearly with time (r 2 = 0.65; P < 0.01). There was no treatment effect on the rate of CO 2 expiration over the 24-h experiment (P = 0.67). The instantaneous oxidative utilization [the time course of TG oxidative utilization, mmol ATP/(kg 0.75 Á min)] of oleic acid TG was greater than that of erucic acid TG (P < 0.006) for both control and clofibrate-treated pigs (Fig. 1B) . There was no statistical difference in peak oxidation rate (P = 0.23) and mean rate (P = 0.14) between the clofibrate-treated and control groups. The oxidative utilization in the pigs increased with time after feeding and peaked at ;5 h for oleic acid TG [436 mmol ATP/(kg 0.75 Á min)], and the utilization rate gradually decreased after 7 h (Fig. 1B) (Fig. 1C) was greater for oleic acid than erucic acid TG (P < 0.001). Although there was no difference in instantaneous oxidative utilization at the peak and mean rates between the 2 groups, the accumulative utilization of the TGs tended to increase in clofibrate-treated pigs (P = 0.10). The estimated TG utilization by clofibrate-treated pigs using the logistic regression model for oleic acid and erucic acid TGs ( Table 1) exceeded controls by 1.5-and 1.3-fold, respectively. Neither clofibrate nor FA chain length had any effect on the time required to reach half-utilization of the TG.
Hepatic FA oxidation. Hepatic mitochondrial FA oxidation was increased in pigs treated with clofibrate ( Fig. 2A) . The 14 C accumulations in CO 2 , ASP, and CO 2 + ASP from oleic acid were 0.6-, 0.8-, and 0.8-fold greater in pigs given clofibrate than in control pigs (P < 0.01), respectively. There was no significant difference in the 14 C accumulation in CO 2 for erucic acid between clofibrate-treated and control pigs, but 14 C accumulation in ASP (and CO 2 + ASP) increased 260% (P < 0.005). The b-oxidation rate of oleic acid was 1.8-fold greater than that of erucic acid (P < 0.001). No interaction was observed between FA chain length and clofibrate (P = 0.4).
In contrast with the FA oxidation in mitochondria, the effect of clofibrate on oxidation in peroxisomes differed for oleic acid and erucic acid substrates (Fig. 2B) . The 14 C accumulation in ASP (and CO 2 + ASP) from oleic acid was 51% greater in clofibrate-treated pigs than in controls (P < 0.07), whereas 14 C accumulation from erucic acid was unaltered by clofibrate (P = 0.45). In addition, there was no difference in peroxisomal b-oxidation between the 2 FAs (P = 0.46). Again, no interaction was detected between FA chain length and clofibrate treatment (P = 0.36), and accumulation of 14 C in CO 2 from both treatments was negligible (<0.37%). There were no significant differences in the total accumulation of 14 CO 2 in either mitochondria or peroxisome incubations (Fig. 2C) . Clofibrate increased total b-oxidation rate (radioactivity accumulated in CO 2 + ASP) by 67% and 77% for oleic acid and erucic acid, respectively (P < 0.001), and the increases were primarily due to the 14 C accumulation in ASP. The 14 C accumulation in CO 2 , ASP, and CO 2 + ASP was higher for oleic acid substrate than for erucic acid substrate (P < 0.005). The total b-oxidation rate was 0.7-fold greater for oleic acid than erucic acid. No interaction was detected between the FA chain length and clofibrate (P = 0.59).
The contribution of peroxisomal b-oxidation (Fig. 3) to the total FA b-oxidation (percentage) was 0.8-fold greater from erucic (82%) than oleic acid (46%) in control pigs. A significant interaction was observed between FA chain length and clofibrate (P < 0.015). Feeding clofibrate reduced the contribution of peroxisomal b-oxidation for erucic acid by 32% (from 82% to 56%; P < 0.0005) but had no impact on the contribution of oleic acid (P = 0.28). The influence of FA chain length and clofibrate on the distribution of peroxisomal b-oxidation was due to the 14 C accumulation in ASP because the proportion of peroxisomal b-oxidation to CO 2 was low (<7%).
Enzyme activity and mRNA expression. The enzyme activities [mmol/(h Á g protein)] were 0.9-fold greater for CPT I measured in mitochondria and 1.2-fold greater for ACO in liver homogenates from clofibrate-treated pigs (170.3 6 7.8 and 65.5 6 5.2) than control pigs (90.4 6 7.8 and 29.5 6 5.2), respectively (means 6 SEMs; P < 0.01). Consistent with the enzyme activities, the relative abundances of mRNA of CPT I and ACO (Fig. 4) also were increased by 3.51-and 2.83-fold, respectively, in the liver of clofibrate-treated pigs (P < 0.04). The induction of mRNA expression of PPARa was observed in the liver of clofibratetreated pigs (P < 0.03). There was no effect of clofibrate on CPT II (P = 0.15).
Discussion
The stimulatory effects of clofibrate, as a pharmaceutical PPARa agonist, on in vitro FA oxidation have been studied extensively, but, to our knowledge, the effects on in vivo FA oxidation were never evaluated in living animals by providing TGs as the FA source. Paul and Adibi (28) demonstrated that clofibrate increased 14 CO 2 production in expired air by 40% after i.v. injection of a trace dose of [
14 C]palmitate, suggesting that clofibrate indeed stimulates in vivo FA oxidation. In contrast, we found that the TG utilization rate (calculated from expired 14 CO 2 ) in clofibrate-treated pigs did not significantly differ from control pigs (P = 0.14), although the utilization rate was 1.5-fold Figure 1C at t = N. greater at peak and 1.3-fold higher over the entire 24-h collection time compared with controls. We showed previously (11) that CPT I, ACO, and catalase increased in liver but not in muscle from neonatal pigs fed clofibrate for 14 d, indicating that the stimulation of FA oxidation in skeletal muscle is less than in the liver. Because skeletal muscle comprises >50% of BW, the utilization of the TGs ingested would occur primarily in the muscle. Thus, the mild response of the muscle to clofibrate stimulation could result in attenuation of whole-body TG utilization in response to clofibrate treatment. In support of this, we did observe in vitro tissue-specific responses to clofibrate as expected and shown in other species (29, 30) .
The FA chain length used in our study may also have influenced our results. Indeed, the accumulative utilization of oleic acid but not erucic acid TG was significantly greater in clofibrate-treated pigs than in control pigs after 12 h (Fig. 1C) . Induction of peroxisomal b-oxidation by clofibrate is relatively small in pigs compared with that in young or adult rodents (11) . Our in vitro data showed that >80% of the erucic acid was oxidized in peroxisomes, and clofibrate did not alter the peroxisomal oxidation rate. It is very interesting that oleic acid oxidation also was substantial in peroxisomes ($46%). Because of the high proportion of peroxisomal oxidation and the low response of peroxisomes to clofibrate induction, the relative contribution of peroxisomal b-oxidation to the total FA oxidation was either reduced from erucic acid or unchanged from oleic acid in response to clofibrate (Fig. 3) . Collectively, we infer that the observed in vivo oxidation rates of oleic acid and erucic acid TGs reflected primarily hepatic effects of clofibrate.
Rats and other animals have a limited capacity to metabolize MUFAs with 22 carbons, such as erucic acid, because of the high TG accumulation rate in extrahepatic tissues and low oxidation rate in the liver (31) . Erucic acid is naturally present in rapeseed oil or hydrogenated fish oil. The digestibility of rapeseed oil and its effects on lipid profile in tissues and histopathology in organs were evaluated in swine (32) (33) (34) (35) , but there is no information on erucic acid oxidation. Swine have high digestion and absorption rates of rapeseed oil and a high proportion of peroxisomal oxidation compared with rodent species (11) . Even so, the data from this study showed that the oxidative utilization of erucic acid TG in vivo was only ;40% of oleic acid TG. This was consistent with our in vitro data in which the hepatic FA oxidation of erucic acid was only 58% of the oleic acid. Considering that neonatal pigs have a high LCFA esterification rate during the suckling period (4), we believe that neonatal pigs might also have a high erucic acid accumulation rate in the tissues, as observed in rodent species (31) .
Hepatic in vitro FA oxidation was increased by clofibrate in both mitochondria and peroxisomes. The increase was consistent with increased mRNA and activity of CPT I and ACO, confirming our previous observations in suckling pigs (12) . These data indicate that the hepatic FA oxidation capacity was enhanced in clofibratetreated pigs, and the results imply that at least part of the increased oxidative utilization of TG observed in vivo was contributed by the increased hepatic FA oxidation. However, the contribution of LCFA and VLCFA in mitochondria was apparently different from that in peroxisomes. Clofibrate increased mitochondria oxidation of both LCFA and VLCFA, but the relative increase was greater for VLCFA (3.6-fold) than for LCFA (1.8-fold). In contrast with mitochondria, clofibrate also increased LCFA oxidation in peroxisomes but had no impact on VLCFA oxidation. Thus, the relative contribution of peroxisomal oxidation to the total oxidation was decreased for VLCFA (Fig. 3) . Dietary LCFAs are oxidized primarily in the mitochondria. Data from previous rat studies indicate that the contribution of hepatic peroxisomal oxidation to total b-oxidation ranges from 20% to 35% for palmitate or oleate (36) . In contrast to rats, pigs have a greater proportion of peroxisomal b-oxidation for LCFAs (40-47%). Our data showed that 46% of oleic acid was oxidized in peroxisomes, and the oxidation rate was surprisingly similar to the rate of erucic acid oxidation (Fig. 2B) . Furthermore, clofibrate stimulated VLCFA oxidation in mitochondria and increased the energy utilization efficiency of VLCFA.
Neonatal pig survival depends on its rapid metabolic adaptation to utilize FAs as its primary postnatal fuel because FAs represent 60% of the total energy in sow milk (37) . The greater peroxisomal b-oxidation capacity observed in piglets and its rapid increase in liver after birth might act as a compensatory mechanism to enhance milk fat oxidation and thermo-adaptation (11, 15) . One of the differences between mitochondrial and peroxisomal b-oxidation is energy generation. Peroxisomal b-oxidation is less coupled to ATP synthesis and therefore more thermogenic (38) . Accordingly, the efficiency of energy generation for complete FA oxidation in peroxisomes could be only 71% of that in mitochondria. Despite this low FA oxidative efficiency, peroxisomal b-oxidation is an important metabolic pathway for multiple functions (39) and is of significance for maintaining thermogenesis (40) (41) (42) . The increase in FA oxidation elicited by clofibrate not only improved the efficiency of energy production from VLCFA but also increased the efficiency of thermogenesis by LCFA.
In conclusion, clofibrate increased accumulative in vivo FA oxidation in the same manner as it was shown to increase in vitro hepatic FA oxidation. Administration of clofibrate significantly increased VLCFA oxidation in mitochondria and LCFA oxidation in peroxisomes. The increases might promote both energy production and chemical thermogenesis. Therefore, natural or synthetic PPARa ligands may prove useful to stimulate FA oxidation and lipid utilization in perinatal pigs.
